Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date28 Jan 2018 |
100 Clinical Results associated with Inner Mongolia Kangenbei Pharmaceutical Co., Ltd. Shenglong Branch
0 Patents (Medical) associated with Inner Mongolia Kangenbei Pharmaceutical Co., Ltd. Shenglong Branch
100 Deals associated with Inner Mongolia Kangenbei Pharmaceutical Co., Ltd. Shenglong Branch
100 Translational Medicine associated with Inner Mongolia Kangenbei Pharmaceutical Co., Ltd. Shenglong Branch